{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:39:39Z","timestamp":1788489579438,"version":"build-2803163510"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2020,3,1]]},"DOI":"10.1001\/jamacardio.2019.4982","type":"journal-article","created":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T13:54:05Z","timestamp":1574085245000},"page":"336","source":"Crossref","is-referenced-by-count":20,"title":["Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril\/Valsartan and Ivabradine in Heart Failure"],"prefix":"10.1001","volume":"5","author":[{"given":"Andrew","family":"Sumarsono","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Heart and Vascular Center and Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezimamaka","family":"Ajufo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"Navar","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"},{"name":"Associate Editor, JAMA Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[{"name":"Associate Editor, JAMA Cardiology"},{"name":"Ahmanson\u2013University of California, Los Angeles Cardiomyopathy Center, University of California Los Angeles Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep R.","family":"Das","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambarish","family":"Pandey","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"13","key":"hbr190021r1","first-page":"e282","article-title":"2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.","volume":"134","author":"Yancy","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"hbr190021r2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jchf.2016.12.018","article-title":"Early adoption of sacubitril\/valsartan for patients with heart failure with reduced ejection fraction: insights from Get With the Guidelines\u2013Heart Failure (GWTG-HF).","volume":"5","author":"Luo","year":"2017","journal-title":"JACC Heart Fail"},{"issue":"4","key":"hbr190021r3","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry.","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"hbr190021r4","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005400","article-title":"Patient, provider, and practice characteristics associated with sacubitril\/valsartan use in the United States.","volume":"11","author":"DeVore","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"15","key":"hbr190021r5","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1001\/jama.2009.1493","article-title":"Use of aldosterone antagonists in heart failure.","volume":"302","author":"Albert","year":"2009","journal-title":"JAMA"},{"key":"hbr190021r7","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2019.2223","article-title":"Assessment of national coverage and out-of-pocket costs for sacubitril\/valsartan under Medicare Part D.","author":"DeJong","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"15","key":"hbr190021r8","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1056\/NEJMp1908688","article-title":"Proposals to redesign Medicare Part D: easing the burden of rising drug prices.","volume":"381","author":"Dusetzina","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"hbr190021r9","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1056\/NEJMp1909798","article-title":"Medicare drug-price negotiation : why now\u2026and how.","volume":"381","author":"Frank","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"hbr190021r10","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamacardio.2016.1747","article-title":"Cost-effectiveness analysis of sacubitril\/valsartan vs enalapril in patients with heart failure and reduced ejection fraction.","volume":"1","author":"Gaziano","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"10","key":"hbr190021r11","doi-asserted-by":"publisher","first-page":"681","DOI":"10.7326\/M16-0057","article-title":"Cost-effectiveness of sacubitril-valsartan in patients with heart failure with reduced ejection fraction.","volume":"165","author":"Sandhu","year":"2016","journal-title":"Ann Intern Med"},{"issue":"9","key":"hbr190021r12","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011089","article-title":"Lower hospitalization and healthcare costs with sacubitril\/valsartan versus angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker in a retrospective analysis of patients with heart failure.","volume":"8","author":"Albert","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"21","key":"hbr190021r13","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1161\/CIRCULATIONAHA.117.027773","article-title":"Scope of sacubitril\/valsartan eligibility after heart failure hospitalization: findings from the GWTG-HF registry (Get With The Guidelines\u2013Heart Failure).","volume":"135","author":"Parikh","year":"2017","journal-title":"Circulation"},{"issue":"5","key":"hbr190021r14","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003221","article-title":"Cost-effectiveness of ivabradine for heart failure in the United States.","volume":"5","author":"Kansal","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"hbr190021r15","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"hbr190021r6","year":"2017"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2755871\/jamacardiology_sumarsono_2019_br_190021_1609877294.89407.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T06:26:01Z","timestamp":1610259961000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2755871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,1]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2019.4982","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3,1]]}}}